Novel role for β-adrenergic signalling in skeletal muscle growth, development and regeneration: Proceedings of the Australian physiological society symposium: Signals mediating exercise-induced skeletal muscle remodelling

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 3, 2010, Pages 397-401

  Ryall, James G ^a,b   Church, Jarrod E ^a   Lynch, Gordon S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

adrenergic signalling; adrenoceptor agonists; Cancer cachexia; Differentiation; Muscle damage; Muscle injury and repair; Muscle regeneration; Muscular dystrophy; Myogenesis; Sarcopenia

Indexed keywords

BETA ADRENERGIC RECEPTOR; SOMATOMEDIN C;

CELL DIFFERENTIATION; CONFERENCE PAPER; ENZYME PHOSPHORYLATION; HUMAN; IN VIVO STUDY; MUSCLE DEVELOPMENT; MUSCLE GROWTH; MUSCLE HYPERTROPHY; MUSCLE REGENERATION; MUSCULAR DYSTROPHY; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; SKELETAL MUSCLE; UPREGULATION; ANIMAL; GROWTH, DEVELOPMENT AND AGING; PHYSIOLOGY; REGENERATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; RECEPTORS, ADRENERGIC, BETA; REGENERATION; SIGNAL TRANSDUCTION;

EID: 77649106681     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05312.x     Document Type: Conference Paper

References (48)

1. Buckingham M, Bajard L, Chang T et al. The formation of skeletal muscle: From somite to limb. J. Anat. 2003 202 : 59 68.
2. Chargé SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol. Rev. 2004 84 : 209 238.
3. Lynch GS, Schertzer JD, Ryall JG. Therapeutic approaches for muscle wasting disorders. Pharmacol. Ther. 2007 113 : 461 487.
4. 2-Adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. J. Appl. Physiol. 2004 96 : 1385 1392.
5. Beitzel F, Sillence MN, Lynch GS. β-Adrenoceptor signaling in regenerating skeletal muscle after β-agonist administration. Am. J. Physiol. Endocrinol. Metab. 2007 293 : E932 40.
6. Lynch GS, Ryall JG. Role of β-adrenoceptor signaling in skeletal muscle. Implications for muscle wasting and disease. Physiol. Rev. 2008 88 : 729 767.
7. Downie D, Delday MI, Maltin CA, Sneddon AA. Clenbuterol increases muscle fiber size and GATA-2 protein in rat skeletal muscle in utero. Mol. Reprod. Dev. 2008 75 : 785 794.
8. 2-adrenoceptor agonists as drugs for the management of muscle wasting. Pharmacol. Ther. 2008 120 : 219 232.
9. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 2005 37 : 1974 1984.
10. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology 2008 23 : 160 170.
11. Kline WO, Panaro FJ, Yang H, Bodine SC. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. J. Appl. Physiol. 2007 102 : 740 747.
12. 2-adrenoceptors in rat skeletal muscles. Biochem. Pharmacol. 1991 42 : 1783 1789.
13. Jensen J, Brørs O, Dahl HA. Different β-adrenergic receptor density in different rat skeletal muscle fibre types. Pharmacol. Toxicol. 1995 76 : 380 385.
14. Garami A, Zwartkruis FJ, Nobukuni T et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 2003 11 : 1457 1466.
15. Latres E, Amini AR, Amini AA et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. 2005 280 : 2737 2744.
16. Stitt TN, Drujan D, Clarke BA et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 2004 14 : 395 403.
17. Sandri M, Sandri C, Gilbert A et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004 117 : 399 412.
18. Sneddon AA, Delday MI, Steven J, Maltin CA. Elevated IGF-II mRNA and phosphorylation of 4E-BP1 and p70 (S6k) in muscle showing clenbuterol-induced anabolism. Am. J. Physiol. Endocrinol. Metab. 2001 281 : E676 82.
19. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001 15 : 807 826.
20. Lecker SH, Jagoe RT, Gilbert A et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 2004 18 : 39 51.
21. Sacheck JM, Hyatt JP, Raffaello A et al. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 2007 21 : 140 155.
22. Moylan JS, Smith JD, Chambers MA, McLoughlin TJ, Reid MB. TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. Am. J. Physiol. Cell Physiol. 2008 295 : C986 93.
23. Buckingham M, Relaix F. The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annu. Rev. Cell Dev. Biol. 2007 23 : 645 673.
24. Bryson-Richardson RJ, Currie PD. The genetics of vertebrate myogenesis. Nat. Rev. Genet. 2008 9 : 632 646.
25. Chen AE, Ginty DD, Fan CM. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature 2005 433 : 317 322.
26. Du M, Perry RLS, Nowacki NB et al. Protein kinase A represses skeletal myogenesis by targeting myocyte enhancer factor 2D. Mol. Cell. Biol. 2008 28 : 2952 2970.
27. Cuenda A, Cohen P. Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J. Biol. Chem. 1999 274 : 4341 4346.
28. Erbay E, Chen J. The mammalian target of rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism. J. Biol. Chem. 2001 276 : 36079 36082.
29. Shu L, Zhang X, Houghton PJ. Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin. J. Biol. Chem. 2002 277 : 16726 16732.
30. Erbay E, Park IH, Nuzzi PD, Schoenherr CJ, Chen J. IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients. J. Cell Biol. 2003 163 : 931 936.
31. Park IH, Chen J. Mammalian target of rapamycin (mTOR) signaling is required for a late-stage fusion process during skeletal myotube maturation. J. Biol. Chem. 2005 280 : 32009 32017.
32. Tomczak KK, Marinescu VD, Ramoni MF et al. Expression profiling and identification of novel genes involved in myogenic differentiation. FASEB J. 2004 18 : 403 405.
33. Chen IH, Huber M, Guan T, Bubeck A, Gerace L. Nuclear envelope transmembrane proteins (NETs) that are up-regulated during myogenesis. BMC Cell Biol. 2006 7 : 38.
34. Spurlock DM, McDaneld TG, McIntyre LM. Changes in skeletal muscle gene expression following clenbuterol administration. BMC Genomics 2006 7 : 320.
35. Auman JT, Seidler FJ, Tate CA, Slotkin TA. Are developing β-adrenoceptors able to desensitize? Acute and chronic effects of β-agonists in neonatal heart and liver. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002 283 : R205 17.
36. Lagercrantz H, Slotkin TA. The 'stress' of being born. Sci. Am. 1986 254 : 100 107.
37. 2-antagonist, on the growth of skeletal muscle of suckling rats. Pflügers Arch. 1995 431 : 237 243.
38. 2-adrenergic receptor. Muscle Nerve 2002 25 : 729 734.
39. 2-adrenergic receptor gene. J. Biol. Chem. 1999 274 : 16694 16700
40. 1-adrenergic receptor gene: Developmental and cardiovascular effects. Proc. Natl Acad. Sci. USA 1996 93 : 7375 7380.
41. Bricout VA, Serrurier BD, Bigard AX. Clenbuterol treatment affects myosin heavy chain isoforms and MyoD content similarly in intact and regenerated soleus muscles. Acta Physiol. Scand. 2004 180 : 271 280.
42. 2-agonist administration enhances early regeneration and functional repair after myotoxic injury in rat skeletal muscle. J. Appl. Physiol. 2008 105 : 165 172.
43. 2-adrenergic receptor mRNA regulates receptor synthesis. J. Biol. Chem. 2004 279 : 27108. 15.
44. Yu J, Cao Q, Mehra R et al. Integrative genomics analysis reveals silencing of β-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007 12 : 419 431.
45. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev. 2004 18 : 2627 2638.
46. 2-agonist administration affects cardiac function of adult but not old rats, independent of β-adrenoceptor density. Am. J. Physiol. Heart Circ. Physiol. 2005 289 : H344 9.
47. 2+-ATPase activity. Am. J. Physiol. Heart Circ. Physiol. 2008 294 : H2587 95.
48. Conklin BR, Hsiao EC, Claeysen S et al. Engineering GPCR signaling pathways with RASSLs. Nat. Methods 2008 5 : 673 678.